Status:
COMPLETED
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Lead Sponsor:
RECORDATI GROUP
Conditions:
Cushings Disease
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients wi...
Eligibility Criteria
Inclusion
- Written informed consent or equivalent document (e.g., written information) as per country regulation prior to registration of any patient data
- Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option
- Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry
Exclusion
- Patients with ectopic ACTH-dependent Cushing's syndrome
- Patients with adrenal Cushing's syndrome
- Patients with Pseudo Cushing's syndrome
Key Trial Info
Start Date :
March 28 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 10 2023
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT02310269
Start Date
March 28 2013
End Date
July 10 2023
Last Update
October 15 2024
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
St Josephs Hospital and Medical Center
Phoenix, Arizona, United States, 85013
2
University of Southern California CSOM230B2410 - SC
Los Angeles, California, United States, 90033
3
Massachusetts General Hospital SC - SOM230B2410
Boston, Massachusetts, United States, 02114
4
Ohio State University SC - SOM230B2410
Columbus, Ohio, United States, 43210